PicturaBio
Pictura Bio is developing the world's first one-minute pathogen detection platform, PIC-ID, leveraging computer vision and machine learning for infectious disease diagnostics. Established in 2022 as a spin-out from the University of Oxford, the company integrates biology, optical engineering, and AI to deliver rapid, accurate, and accessible diagnostic tests at the point of care. Their platform consists of PIC-ID Capture (a universal reagent for pathogen binding), VISTA Reader (a digital image capture and processing device using fluorescence microscopy), and PIC-ID Identify (a deep learning algorithm for image analysis). This technology aims to significantly reduce diagnostic turnaround times from hours or days to under a minute, simplify testing by using a single reagent, and improve patient triage and treatment decisions, addressing critical issues in healthcare like antimicrobial resistance and the accessibility of essential health services. Pictura Bio has secured £2.6 million in pre-seed funding and is progressing through clinical trials and prototype development, with a US subsidiary established for market access. They are positioned as a global front-runner in the image-based infectious disease diagnostics field, with a significant market opportunity in the expanding global infectious disease diagnostics market.
PicturaBio
Pictura Bio is developing the world's first one-minute pathogen detection platform, PIC-ID, leveraging computer vision and machine learning for infectious disease diagnostics. Established in 2022 as a spin-out from the University of Oxford, the company integrates biology, optical engineering, and AI to deliver rapid, accurate, and accessible diagnostic tests at the point of care. Their platform consists of PIC-ID Capture (a universal reagent for pathogen binding), VISTA Reader (a digital image capture and processing device using fluorescence microscopy), and PIC-ID Identify (a deep learning algorithm for image analysis). This technology aims to significantly reduce diagnostic turnaround times from hours or days to under a minute, simplify testing by using a single reagent, and improve patient triage and treatment decisions, addressing critical issues in healthcare like antimicrobial resistance and the accessibility of essential health services. Pictura Bio has secured £2.6 million in pre-seed funding and is progressing through clinical trials and prototype development, with a US subsidiary established for market access. They are positioned as a global front-runner in the image-based infectious disease diagnostics field, with a significant market opportunity in the expanding global infectious disease diagnostics market.